Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Bert H O'Neil Clear advanced filters

  • For patients with colorectal cancer and liver metastases, hepatic resection is the only potential curable treatment. The role of adjuvant chemotherapy in this setting is still under debate. The authors of this Viewpoint discuss the final results of the EORTC Intergroup randomized phase III study 40983 and whether FOLFOX4 should be the new standard in patients with resectable colorectal cancer and liver metastases.

    • Bert H O'Neil
    • Richard M Goldberg
    Reviews
    Nature Clinical Practice Oncology
    Volume: 6, P: 14-16

  • Treatment of KRASG12C-mutant cancer cells with the KRAS(G12C) inhibitor AMG 510 leads to durable response in mice, and anti-tumour activity in patients suggests that AMG 510 could be effective in patients for whom treatments are currently lacking.

    • Jude Canon
    • Karen Rex
    • J. Russell Lipford
    Research
    Nature
    Volume: 575, P: 217-223

  • The optimal therapy for patients with metastatic and treatment-refractory colorectal cancer is controversial. Questions with regard to both the sequence and combinations of different drugs need to be answered by well-designed and adequately powered studies before the most appropriate option for second-line treatment for these patients can be defined.

    • Richard M. Goldberg
    • Bert H. O'Neil
    News & Views
    Nature Reviews Gastroenterology & Hepatology
    Volume: 6, P: 507-509